封面
市場調查報告書
商品編碼
1460814

青蒿酸市場-全球產業規模、佔有率、趨勢、機會和預測,按類型(全合成、半合成)、按應用(抗瘧注射劑、抗瘧片)、按地區、按競爭細分,2019-2029F

Artemisinic Acid Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Total Synthesis, Semi synthesis), By Applications (Antimalarial Injections, Antimalarial Tablets), By Region, By Competition, 2019-2029F

出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023年全球青蒿酸市場價值為5.0134億美元,預計在預測期內將強勁成長,到2029年複合CAGR為4.10%。該市場的擴張是由低度開發和發展中經濟體廣泛的瘧疾負擔推動的,以及許多關於瘧疾的研究以及世界衛生組織和聯合國兒童基金會等著名公共組織領導的計劃。這些組織正在積極努力提高人們對瘧疾治療的認知並控制其在全球的發病率。

主要市場促進因素

根除瘧疾的努力

目錄

第 1 章:產品概述

第 2 章:研究方法

第 3 章:執行摘要

第 4 章:客戶之聲

第 5 章:全球青蒿酸市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按類型(全合成、半合成)
    • 依應用(抗瘧注射劑、抗瘧片)
    • 按地區(中東非洲、亞太地區、南美洲、歐洲、北美)
    • 按公司分類 (2023)
  • 市場地圖
    • 按類型
    • 按應用
    • 按地區

第 6 章:中東與非洲青蒿酸市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按類型
    • 按應用
    • 按國家/地區
  • MEA:國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 7 章:亞太地區青蒿酸市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按類型
    • 按應用
    • 按國家/地區
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 8 章:南美洲青蒿酸市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按類型
    • 按應用
    • 按國家/地區
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章:歐洲青蒿酸市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按類型
    • 按應用
    • 按國家/地區
  • 歐洲:國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 10 章:北美青蒿酸市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按類型
    • 按應用
    • 按國家/地區
  • 北美:國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 11 章:市場動態

  • 促進要素
  • 挑戰

第 12 章:市場趨勢發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章:全球青蒿酸市場:SWOT 分析

第 14 章:波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章:競爭格局

  • Sanofi SA
  • KPC Pharmaceuticals, Inc
  • Guilin Pharmaceutical Co., Ltd
  • Calyx Chemicals and Pharmaceuticals Ltd.
  • Novartis AG
  • Ipca Laboratories Ltd.
  • Cipla Inc.
  • Shin Poong Pharm Co., Ltd.
  • Rupus Global Limited
  • AdvacarePharma

第 16 章:策略建議

第 17 章:關於我們免責聲明

簡介目錄
Product Code: 16108

Global Artemisinic Acid Market was valued at USD 501.34 Million in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 4.10% through 2029. The expansion of this market is driven by the extensive malaria burden in underdeveloped and developing economies, as well as by numerous research studies on malaria and initiatives spearheaded by prominent public organizations such as WHO and UNICEF. These organizations are actively working to raise awareness about malaria treatment and control its incidence worldwide.

Key Market Drivers

Malaria Eradication Efforts

Malaria eradication efforts have led to a heightened demand for ACTs, which are considered the frontline treatment for the disease. Artemisinin, derived from artemisinic acid, is a key component of these therapies. As the global health community strives to reduce the burden of malaria, the demand for ACTs has risen, consequently driving the demand for artemisinic acid as a primary precursor in their production. The emphasis on malaria eradication has prompted pharmaceutical companies, governments, and research organizations to invest in expanding the production capacities for artemisinin-based medicines. This has led to increased production of artemisinic acid, both from natural sources and through innovative biotechnological methods, in order to meet the rising demand for anti-malarial treatments. Malaria eradication efforts have underscored the importance of establishing stable and sustainable supply chains for essential medicines like artemisinin-based drugs. The cultivation of Artemisia annua plants and the extraction of artemisinic acid have become focal points in ensuring a consistent supply of anti-malarial medications. This has contributed to the growth of the artemisinic acid market as efforts are made to secure raw material sources. Global health organizations, governments, and pharmaceutical companies have joined forces to support collaborative initiatives aimed at eradicating malaria. These partnerships facilitate research, development, and production of artemisinin-based treatments, driving investment and innovation in the artemisinic acid market. Malaria-endemic regions have witnessed increased attention and resources as part of malaria eradication efforts. This focus on regions with high malaria prevalence has led to greater accessibility to artemisinin-based treatments, propelling demand for artemisinic acid and driving market growth. Malaria eradication efforts have accelerated research and development in the field of anti-malarial drugs. This includes advancements in production technologies, such as the use of synthetic biology to engineer microorganisms for artemisinic acid production. These technological innovations contribute to increased efficiency and scalability in the artemisinic acid market.

Pharmaceutical Industry Expansion

As the pharmaceutical industry expands, there is a growing emphasis on developing and producing effective medications to address global health challenges. Artemisinin-based combination therapies (ACTs) have gained prominence as vital tools in combating malaria, driving the demand for artemisinic acid, which is an essential precursor in artemisinin production. The pharmaceutical industry's expansion has led to substantial investments in research and development (RD) for new drugs and treatments. The focus on improving the efficiency and cost-effectiveness of artemisinin production has spurred innovative approaches, such as biotechnology and synthetic biology, which impact the production of artemisinic acid and its derivatives. As the pharmaceutical sector grows, so does the need to scale up production to meet the increasing demand for medications. Artemisinic acid, as a precursor for artemisinin, plays a crucial role in this supply chain. The pharmaceutical industry's expertise in optimizing production processes has contributed to the efficient and reliable production of artemisinic acid. The pharmaceutical industry's expansive distribution networks enable the widespread availability of anti-malarial drugs containing artemisinin. This extensive reach ensures that artemisinin-based treatments reach even remote areas affected by malaria, thereby driving the demand for artemisinic acid. Pharmaceutical companies continuously innovate by developing new formulations and dosage forms for medications. This innovation has led to the creation of various artemisinin-based drugs with improved efficacy, dosage regimens, and patient compliance. These advancements stimulate the market for artemisinic acid. As the pharmaceutical industry expands, collaborations between companies, research institutions, and governments become more prevalent. These partnerships contribute to knowledge exchange, technology transfer, and shared resources, ultimately leading to advancements in artemisinic acid production techniques and increased market growth. The pharmaceutical industry's expansion aids in addressing challenges such as drug resistance. By producing artemisinin-based therapies with high efficacy, the industry helps combat emerging resistance to anti-malarial drugs, thereby maintaining the relevance and demand for artemisinic acid.

Increasing Research and Development Advancements

Advancements in RD have led to the development of novel and more efficient production techniques for artemisinic acid. Synthetic biology, genetic engineering, and metabolic engineering approaches have been harnessed to engineer microorganisms capable of producing artemisinic acid. These techniques have not only streamlined production processes but also ensured a more consistent and scalable supply. RD efforts have focused on improving the yield and purity of artemisinic acid extraction. Through genetic optimization and cultivation practices, researchers have achieved higher yields of artemisinic acid from Artemisia annua plants. Additionally, purification techniques have been refined, resulting in higher-quality precursor material for artemisinin synthesis. RD innovations have driven cost efficiency in artemisinic acid production. This cost-effectiveness translates to more accessible and affordable artemisinin-based treatments, which are essential for malaria-endemic regions. The reduced production costs, in turn, support the growth of the artemisinic acid market. RD advancements have enabled the exploration of new artemisinin derivatives and analogs with potentially enhanced therapeutic properties. These derivatives expand the application of artemisinic acid beyond traditional anti-malarial medications, creating opportunities for diversification and market growth. The focus on sustainability has driven RD efforts to develop eco-friendly and renewable approaches to artemisinic acid production. Techniques that minimize the environmental impact, such as plant tissue culture and bioreactors, align with global sustainability goals and contribute to the market's growth. RD advancements in artemisinic acid production have accelerated drug development timelines. Faster and more efficient production methods enable quicker access to essential anti-malarial treatments, meeting urgent healthcare needs and spurring market growth. RD progress in artemisinic acid production technologies has led to the creation of valuable intellectual property. Licensing agreements and collaborations for technology transfer play a role in the commercialization and expansion of the artemisinic acid market.

Key Market Challenges

Supply Chain Vulnerability

Artemisinic acid is primarily sourced from the Artemisia annua plant, which is cultivated under specific agroclimatic conditions. Environmental factors such as weather variations, pests, and diseases can impact crop yields. Uncertain crop yields can lead to supply shortages and contribute to market instability. Global supply chains are subject to geopolitical disruptions, including trade restrictions, tariffs, and political instability in key sourcing regions. Such disruptions can interrupt the flow of artemisinic acid from production centers to manufacturing facilities, affecting the availability of artemisinin-based treatments. The heavy reliance on Artemisia annua plants as the primary source of artemisinic acid creates a single point of failure in the supply chain. Any disruption in plant cultivation, whether due to natural disasters or other factors, can have cascading effects on the production of artemisinin and related medicines. Artemisia annua cultivation is often seasonal, leading to cyclical fluctuations in artemisinic acid availability. This can result in challenges in maintaining a steady supply of artemisinin-based treatments throughout the year, particularly during peak malaria transmission seasons. Artemisinic acid cultivation is typically concentrated in malaria-endemic regions. Non-endemic regions may face challenges in accessing a consistent supply of artemisinic acid due to geographical limitations and limited infrastructure for cultivation and production. Climate change can alter agroclimatic conditions, affecting the growth and yield of Artemisia annua plants. Unpredictable weather patterns and changing temperature regimes may lead to reduced crop productivity, exacerbating supply chain vulnerabilities. Insufficient infrastructure for cultivation, harvesting, and processing of Artemisia annua plants can lead to inefficiencies in the supply chain. Lack of proper storage facilities, transportation options, and processing capabilities can hinder the timely and efficient delivery of artemisinic acid to manufacturers. Maintaining consistent quality and purity of artemisinic acid is essential for producing high-quality artemisinin-based medications. Supply chain vulnerabilities can compromise the quality control processes, leading to variability in the final product. Supply chain disruptions can lead to market instability and price fluctuations for artemisinic acid. This volatility can impact production costs and profitability, discouraging investment and innovation in the market.

Complex Production Processes

The complexity of production processes for artemisinic acid can contribute to elevated production costs. Sophisticated chemical synthesis methods, as well as the need for precise purification and quality control, can increase the overall expenses associated with producing artemisinic acid, affecting market viability. Intricate production methods can present challenges when scaling up production to meet increasing demand. Processes that work efficiently in laboratory settings might not be easily scalable for large-scale commercial production, leading to production bottlenecks. Complex production processes often require specialized technological expertise and skilled personnel. The availability of such expertise can be limited, potentially hindering the adoption and implementation of advanced production techniques. Elaborate production processes can result in longer production timelines from start to finish. Lengthy processing times can delay the availability of artemisinic acid for further conversion into artemisinin and subsequent drug formulation. The complexity of production processes may introduce variability in product quality and yield. Variability can impact the consistency of artemisinic acid supply, leading to challenges in maintaining the quality and efficacy of artemisinin-based medications. Complex production processes might require compliance with intricate regulatory standards and quality control measures. Meeting these standards can add a layer of complexity and potential delays to the production and distribution of artemisinic acid. The intricacies of production processes can serve as barriers to entry for new players in the market. Small and emerging companies might find it challenging to invest in the necessary infrastructure and expertise, limiting market competition and innovation. The complexity of production processes can slow down the pace of innovation. Developing and implementing new and more efficient production methods require significant time and resources, potentially delaying advancements in the field.

Key Market Trends

Synthetic Biology and Biotechnology

Synthetic biology enables the engineering of microorganisms to produce artemisinic acid through fermentation processes. This approach offers higher production yields and faster turnaround times compared to traditional plant cultivation. As a result, artemisinic acid can be produced more efficiently, meeting the growing demand for artemisinin-based treatments. Biotechnological methods allow for the scalable production of artemisinic acid, reducing the limitations posed by natural plant cultivation. This scalability ensures a stable and consistent supply of the precursor, mitigating supply chain vulnerabilities and enabling manufacturers to meet global healthcare needs. Synthetic biology and biotechnology align with sustainability goals by minimizing the environmental impact associated with traditional crop cultivation. These methods require less land, water, and pesticides, contributing to more eco-friendly and resource-efficient production of artemisinic acid. Natural sources of artemisinic acid, such as Artemisia annua, are constrained by agroclimatic conditions and limited cultivation capacities. Synthetic biology allows production in controlled environments, overcoming these limitations and expanding the potential for artemisinic acid production. Researchers are leveraging synthetic biology techniques to engineer microorganisms for optimal artemisinic acid production. Genetic modifications and metabolic engineering enable the development of high-yield strains that efficiently convert precursors into artemisinic acid, improving overall production efficiency. Synthetic biology and biotechnology trends encourage collaboration between academia, research institutions, and private sector companies. Knowledge and technology transfer accelerate innovation, leading to the development of cutting-edge production methods and fostering a dynamic market ecosystem. Biotechnology allows for precise genetic modifications, enabling the tailoring of production strains for specific outputs and properties. This customization opens doors to the creation of specialized artemisinic acid variants with enhanced characteristics. The potential for groundbreaking advancements in artemisinic acid production through synthetic biology has attracted significant investments and funding. This influx of resources fosters innovation and market growth by supporting research and commercialization efforts. The integration of synthetic biology and biotechnology aligns with global efforts to address healthcare challenges sustainably. By offering a more efficient and environmentally friendly approach to artemisinic acid production, these trends contribute to the broader goal of global health and well-being.

Diversification of End Products

The diversification of artemisinic acid applications expands the market's potential beyond anti-malarial drugs. By addressing a broader range of industries, including cosmetics, nutraceuticals, and pharmaceuticals, the market gains access to new customer segments and revenue streams. Relying solely on the production of artemisinin for anti-malarial treatments can expose the market to risks such as supply chain vulnerabilities and market fluctuations. Diversifying end products helps mitigate risks by reducing dependence on a single application, promoting market resilience. The introduction of new artemisinic acid derivatives and applications allows companies to differentiate themselves in a competitive market. Innovative products cater to specific consumer needs and demands, enhancing a company's brand and market positioning. Diversified end products align with health and wellness trends, driving demand for natural and plant-derived ingredients. Nutraceuticals and dietary supplements benefit from the inclusion of artemisinic acid, leveraging its potential health benefits beyond malaria treatment. Artemisinic acid's antioxidant properties make it a valuable ingredient in cosmetics and skincare products. Its potential to enhance skin health and reduce oxidative stress positions it as a sought-after ingredient in the personal care industry. Researchers are exploring the use of artemisinic acid in various scientific and biotechnological applications. The compound's unique properties make it valuable for use in laboratory settings and research experiments, further expanding its utility. Diversification of end products enhances the market's resilience during health crises. While anti-malarial treatments remain crucial, the availability of other products helps balance demand and supply dynamics during emergencies.

Segmental Insights

Applications Insights

Based on the Applications, the antimalarial tablets segment is anticipated to witness substantial market growth throughout the forecast period.

The use of antimalarial tablets drives the demand for artemisinin, which is a primary ingredient in artemisinin-based combination therapies (ACTs). As malaria remains a significant global health challenge, the sustained demand for effective antimalarial treatments contributes to the growth of the artemisinic acid market. The consistent and ongoing demand for antimalarial tablets provides market stability and predictability for artemisinic acid producers. This stability encourages investments in research, production, and innovation, fostering a conducive environment for market growth. The continuous need for effective antimalarial treatments incentivizes ongoing research and innovation in the artemisinic acid market. Companies and research institutions are motivated to improve production techniques, optimize supply chains, and enhance the overall efficiency of artemisinin-based therapies. Antimalarial tablets are a cornerstone of global health initiatives aimed at combating malaria. These initiatives drive funding, collaborations, and partnerships that support artemisinic acid production, ensuring a steady supply of essential medications. The demand for antimalarial tablets encourages the integration of new technologies in artemisinin production. Synthetic biology, biotechnology, and advanced extraction methods are adopted to streamline production processes and enhance the efficiency of artemisinic acid production. The success of antimalarial tablets opens doors to explore applications of artemisinic acid beyond malaria treatment. As research expands, the compound's potential for other therapeutic uses, such as anticancer properties, could drive additional market growth. The demand for antimalarial tablets aligns regulatory frameworks to ensure the quality, safety, and efficacy of artemisinin-based treatments. Regulatory compliance contributes to a robust and trustworthy market environment. Partnerships between pharmaceutical companies, governments, and global health organizations leverage the demand for antimalarial tablets to drive joint initiatives. These collaborations stimulate investments, research, and knowledge-sharing, boosting the growth of the artemisinic acid market.

Regional Insights

Middle East Africa, specifically the Artemisinic Acid Market, dominated the market in 2023, primarily due to The MEA region bears a substantial malaria burden, with several countries facing high transmission rates. This prevalence drives the demand for effective antimalarial treatments, including those derived from artemisinic acid. The region's demand contributes significantly to the global consumption of artemisinin-based medications. Some countries in the MEA region have suitable agroclimatic conditions for cultivating Artemisia annua, the plant source of artemisinic acid. Leveraging this potential for local production can enhance the region's contribution to the global artemisinic acid supply chain. The growth of the artemisinic acid market in the MEA region aligns with economic development initiatives. Improving access to essential medicines, including artemisinin-based treatments, contributes to healthcare advancements and demonstrates the region's commitment to public health. Governments and international organizations in the MEA region are actively involved in public health initiatives to combat malaria. These initiatives drive partnerships, funding, and collaborative efforts that support the growth of the artemisinic acid market. The regulatory landscape in the MEA region can influence the ease of production, distribution, and access to artemisinic acid and its derivatives. Harmonizing regulations and ensuring compliance can facilitate market growth and streamline cross-border trade. Collaborations between countries within the MEA region and international organizations strengthen the artemisinic acid market. Regional partnerships can drive knowledge-sharing, technology transfer, and sustainable supply chain development. Raising public awareness about malaria and the availability of artemisinin-based treatments is crucial in the MEA region. Educational campaigns promote early diagnosis, treatment adherence, and preventive measures, supporting the growth of the market.

Key Market Players

Sanofi SA

KPC Pharmaceuticals, Inc

Guilin Pharmaceutical Co., Ltd

Calyx Chemicals and Pharmaceuticals Ltd.

Novartis AG

Ipca Laboratories Ltd.

Cipla Inc.

Shin Poong Pharm Co., Ltd.

Rupus Global Limited

AdvacarePharma

Report Scope:

In this report, the Global Artemisinic Acid Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artemisinic Acid Market,By Type:

  • Total Synthesis
  • Semi synthesis

Artemisinic Acid Market,By Applications:

  • Antimalarial Injections
  • Antimalarial Tablets

Artemisinic Acid Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Artemisinic Acid Market.

Available Customizations:

Global Artemisinic Acid market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.GlobalArtemisinic Acid MarketOutlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Type (Total Synthesis,Semi synthesis)
    • 5.2.2.By Applications (Antimalarial Injections, Antimalarial Tablets)
    • 5.2.3.By Region (Middle East Africa, Asia Pacific, South America, Europe, North America)
    • 5.2.4.By Company (2023)
  • 5.3.Market Map
    • 5.3.1 By Type
    • 5.3.2 By Applications
    • 5.3.3 By Region

6.Middle East and Africa Artemisinic Acid Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Type (Total Synthesis, Semi synthesis)
    • 6.2.2.By Applications (Antimalarial Injections, Antimalarial Tablets)
    • 6.2.3.By Country
  • 6.3.MEA: Country Analysis
    • 6.3.1.South Africa Artemisinic Acid Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.ByType
        • 6.3.1.2.2.By Applications
    • 6.3.2.Saudi Arabia Artemisinic Acid Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.ByType
        • 6.3.2.2.2.By Applications
    • 6.3.3.UAE Artemisinic Acid Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.ByType
        • 6.3.3.2.2.By Applications

7.Asia-Pacific Artemisinic Acid Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Type (Total Synthesis, Semi synthesis)
    • 7.2.2.By Applications (Antimalarial Injections, Antimalarial Tablets)
    • 7.2.3.By Country
  • 7.3.Asia-Pacific: Country Analysis
    • 7.3.1.China Artemisinic Acid Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.ByType
        • 7.3.1.2.2.By Applications
    • 7.3.2.India Artemisinic Acid Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.ByType
        • 7.3.2.2.2.By Applications
    • 7.3.3.Japan Artemisinic Acid Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.ByType
        • 7.3.3.2.2.By Applications
    • 7.3.4.South Korea Artemisinic Acid Market Outlook
      • 7.3.4.1.Market Size Forecast
        • 7.3.4.1.1.By Value
      • 7.3.4.2.Market Share Forecast
        • 7.3.4.2.1.ByType
        • 7.3.4.2.2.By Applications
    • 7.3.5.Australia Artemisinic Acid Market Outlook
      • 7.3.5.1.Market Size Forecast
        • 7.3.5.1.1.By Value
      • 7.3.5.2.Market Share Forecast
        • 7.3.5.2.1.ByType
        • 7.3.5.2.2.By Applications

8.South America Artemisinic Acid Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Type (Total Synthesis, Semi synthesis)
    • 8.2.2.By Applications (Antimalarial Injections, Antimalarial Tablets)
    • 8.2.3.By Country
  • 8.3.South America: Country Analysis
    • 8.3.1.Brazil Artemisinic Acid Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.ByType
        • 8.3.1.2.2.By Applications
    • 8.3.2.Argentina Artemisinic Acid Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.ByType
        • 8.3.2.2.2.By Applications
    • 8.3.3.Colombia Artemisinic Acid Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.ByType
        • 8.3.3.2.2.By Applications

9.Europe Artemisinic Acid Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Type (Total Synthesis, Semi synthesis)
    • 9.2.2.By Applications (Antimalarial Injections, Antimalarial Tablets)
    • 9.2.3.By Country
  • 9.3.Europe: Country Analysis
    • 9.3.1.France Artemisinic Acid Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.ByType
        • 9.3.1.2.2.By Applications
    • 9.3.2.Germany Artemisinic Acid Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.ByType
        • 9.3.2.2.2.By Applications
    • 9.3.3.United Kingdom Artemisinic Acid Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.ByType
        • 9.3.3.2.2.By Applications
    • 9.3.4.Italy Artemisinic Acid Market Outlook
      • 9.3.4.1.Market Size Forecast
        • 9.3.4.1.1.By Value
      • 9.3.4.2.Market Share Forecast
        • 9.3.4.2.1.ByType
        • 9.3.4.2.2.By Applications
    • 9.3.5.Spain Artemisinic Acid Market Outlook
      • 9.3.5.1.Market Size Forecast
        • 9.3.5.1.1.By Value
      • 9.3.5.2.Market Share Forecast
        • 9.3.5.2.1.ByType
        • 9.3.5.2.2.By Applications

10.North America Artemisinic Acid Market Outlook

  • 10.1.Market Size Forecast
    • 10.1.1.By Value
  • 10.2.Market Share Forecast
    • 10.2.1.By Type (Total Synthesis, Semi synthesis)
    • 10.2.2.By Applications (Antimalarial Injections, Antimalarial Tablets)
    • 10.2.3.By Country
  • 10.3.North America: Country Analysis
    • 10.3.1.United States Artemisinic Acid Market Outlook
      • 10.3.1.1.Market Size Forecast
        • 10.3.1.1.1.By Value
      • 10.3.1.2.Market Share Forecast
        • 10.3.1.2.1.ByType
        • 10.3.1.2.2.By Applications
    • 10.3.2.Canada Artemisinic Acid Market Outlook
      • 10.3.2.1.Market Size Forecast
        • 10.3.2.1.1.By Value
      • 10.3.2.2.Market Share Forecast
        • 10.3.2.2.1.ByType
        • 10.3.2.2.2.By Applications
    • 10.3.3.Mexico Artemisinic Acid Market Outlook
      • 10.3.3.1.Market Size Forecast
        • 10.3.3.1.1.By Value
      • 10.3.3.2.Market Share Forecast
        • 10.3.3.2.1.ByType
        • 10.3.3.2.2.By Applications

11.Market Dynamics

  • 11.1.Drivers
  • 11.2.Challenges

12.Market Trends Developments

  • 12.1.Recent Development
  • 12.2.Mergers Acquisitions
  • 12.3.Product Launches

13.Global Artemisinic Acid Market: SWOT Analysis

14.Porter's Five Forces Analysis

  • 14.1.Competition in the Industry
  • 14.2.Potential of New Entrants
  • 14.3.Power of Suppliers
  • 14.4.Power of Customers
  • 14.5.Threat of Substitute Products

15.Competitive Landscape

  • 15.1.Sanofi SA
    • 15.1.1.Business Overview
    • 15.1.2.Product Offerings
    • 15.1.3.Recent Developments
    • 15.1.4.Financials (As Reported)
    • 15.1.5.Key Personnel
    • 15.1.6.SWOT Analysis
  • 15.2.KPC Pharmaceuticals, Inc
  • 15.3.Guilin Pharmaceutical Co., Ltd
  • 15.4.Calyx Chemicals and Pharmaceuticals Ltd.
  • 15.5.Novartis AG
  • 15.6.Ipca Laboratories Ltd.
  • 15.7.Cipla Inc.
  • 15.8.Shin Poong Pharm Co., Ltd.
  • 15.9.Rupus Global Limited
  • 15.10.AdvacarePharma

16.Strategic Recommendations

17.About Us Disclaimer